Clinical trials: Resectable Pancreatic Cancer
Pancreatic Cancer
Margin-Intense Combo Therapy in Pts w/Potentially Resectable Pancreatic Cancer
RATIONALE: Stereotactic body radiation therapy may be able to send x-rays directly to the tumor and cause less damage to normal tissue.
- Trial name
- NCT01025882
- Testing
- gemcitabine hydrochloride, stereotactic body radiation therapy
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- University of Texas Southwestern Medical Center
Pancreatic Carcinoma Non-resectable, Stage IV Pancreatic Cancer
Study to Evaluate Bi-weekly Dosing of Gemcitabine Plus Nab-Paclitaxel to Treat Metastatic Pancreatic Cancer
To determine whether the occurrence of adverse events can be decreased by moving to a bi-weekly schedule of gemcitabine plus nab-Pacitaxel for the treatment of unresectable/metastatic pancreatic cancer.
- Trial name
- NCT01851174
- Testing
- Gemcitabine, nab-Paclitaxel
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- Western Regional Medical Center